Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Roflumilast
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Sol-Gel Technologies
Deal Size : Inapplicable
Deal Type : Inapplicable
Sol-Gel's Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve® Cream
Details : Zoryve-Generic (roflumilast), PDE4 Inhibitor, small molecule. It is a topical cream indicated for the treatment of plaque psoriasis in patients six years of age and older.
Product Name : Zoryve-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 04, 2024
Lead Product(s) : Roflumilast
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Sol-Gel Technologies
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Brinzolamide
Therapeutic Area : Ophthalmology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Padagis Announces the Launch of Brinzolamide Ophthalmic Suspension with CGT Exclusivity
Details : Brinzolamide, generic equivalent to the Reference Listed Drug Azopt Ophthalmic Suspension, is indicated to decrease elevated intraocular pressure (IOP) in adult patients with ocular hypertension or open-angle glaucoma.
Product Name : Azopt-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 13, 2023
Lead Product(s) : Brinzolamide
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Naloxone Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Padagis Announces the First Launch of an Over-the-counter Naloxone Nasal Spray in The United States
Details : Naloxone HCl Nasal Spray is the opioid antagonists indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression.
Product Name : Narcan-Generic
Product Type : Controlled Substance
Upfront Cash : Inapplicable
August 08, 2023
Lead Product(s) : Naloxone Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Naloxone Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Padagis Announces the First Generic Over-the-Counter Approval of a Naloxone Nasal Spray Product
Details : Naloxone hydrochloride nasal spray, as an OTC emergency treatment for known or suspected opioid overdose. Naloxone hydrochloride is an opioid antagonist that antagonizes opioid effects by competing for the same receptor sites, which is investigated for t...
Product Name : Narcan-Generic
Product Type : Controlled Substance
Upfront Cash : Inapplicable
July 19, 2023
Lead Product(s) : Naloxone Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Budesonide
Therapeutic Area : Immunology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Budesonide is a prescription corticosteroid medicine used to help get active, mild to moderate ulcerative colitis that extends from the rectum to the sigmoid colon under control (induce remission).
Product Name : Uceris-Generic
Product Type : Steroid
Upfront Cash : Inapplicable
April 28, 2023
Lead Product(s) : Budesonide
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Roflumilast
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Bioequivalence Study of Two Treatments for the Treatment of Plaque Psoriasis
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 10, 2023
Lead Product(s) : Roflumilast
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Naloxone Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Padagis Announces 3 Major Product Launches
Details : Naloxone Nasal Spray, 4mg (generic to Narcan®),is a prescription medicine used for the treatment of a known or suspected opioid overdose emergency with signs of breathing problems and severe sleepiness or not being able to respond.
Product Name : Narcan-Generic
Product Type : Controlled Substance
Upfront Cash : Inapplicable
June 21, 2022
Lead Product(s) : Naloxone Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Terbinafine Hydrochloride
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Recipient : Moberg Pharma
Deal Size : Undisclosed
Deal Type : Agreement
Moberg Pharma and Padagis Sign Agreement For MOB-015 in Israel
Details : Under the agreement Padagis is granted exclusive rights to market and sell MOB-015 (terbinafine hydrochloride) in Israel and the Palestinian territories. Moberg Pharma assumes production and supply responsibility.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
April 08, 2022
Lead Product(s) : Terbinafine Hydrochloride
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Recipient : Moberg Pharma
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Tobramycin,Dexamethasone
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Tobramycin (generic to Tobradex) Ophthalmic Suspension is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exi...
Product Name : Tobramycin / Dexamethasone-Generic
Product Type : Antibiotic
Upfront Cash : Inapplicable
March 21, 2022
Lead Product(s) : Tobramycin,Dexamethasone
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tobramycin,Dexamethasone
Therapeutic Area : Immunology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Tobradex® Ophthalmic Suspension is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists.
Product Name : Tobramycin / Dexamethasone-Generic
Product Type : Antibiotic
Upfront Cash : Inapplicable
March 21, 2022
Lead Product(s) : Tobramycin,Dexamethasone
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable